KOL

Psychedelics set to be the revolutionary treatments in pscyhiatry - Thelansis Knowledge Partners

Retrieved on: 
Thursday, February 22, 2024
Knowledge, DSM-IV codes, Esketamine, TRD, Major depressive disorder, Drug development, TAS, USFDA, Psilocybin, MDMA, Psychiatry, CNS, Patient, Acute stress disorder, PTSD, Polypharmacy, Psychotherapy, MDD, KOL, Research, Central nervous system disease, Pharmaceutical industry

Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."

Key Points: 
  • Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."
  • According to an interviewed U.S.-based neurologist by Thelansis – "We desperately need disease-modifying treatments for many neurodegenerative conditions.
  • As psychedelics would be beneficial for treatment-nonresponders or severe patients, the commercial opportunities are multiple for in-pipeline psychedelic therapies.
  • What is the probable opportunity for Psychedelics (e.g., psilocybin, MDMA) to address the unmet needs of other TAs?

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

Retrieved on: 
Wednesday, February 14, 2024
PD, Newcastle University, Analyst, Research, University Medical Center, Internet, PI, Synucleinopathy, Biomarker, Therapy, Genetics, Task force, Columbia University, KOL, Symptomatic treatment, Pharmaceutical industry

“Beyond Symptomatic Treatment of Parkinson’s Disease: Gain Therapeutics R&D Update with KOL & Analyst Insights 2024”

Key Points: 
  • “Beyond Symptomatic Treatment of Parkinson’s Disease: Gain Therapeutics R&D Update with KOL & Analyst Insights 2024”
    GBA-associated Parkinson’s Disease & other Synucleinopathies: current unmet medical needs and needed therapies.
  • Discussion of recent in vivo data for GT-02287 as a best-in-class small molecule, for the treatment of GBA-Parkinson’s Disease and other neurodegenerative diseases.
  • His research interests are focused on the understanding of the molecular mechanisms of neurodegenerative diseases such as Parkinson’s, Huntington’s, and Alzheimer’s disease.
  • He is Chair of the Task Force on the Biological Definition of Parkinson’s Disease of Internation Parkinson and Movement Disorder Society.

Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024

Retrieved on: 
Wednesday, February 14, 2024
Fibromyalgia, Tonix Pharmaceuticals, FDA, Pain, Food, Sleep, Behavioral neuroscience, Hope, Hydrogen chloride, University, Fatigue, Patient, University of Cincinnati, University of Michigan, Psychiatry, Tablet, NDA, KOL, Pharmaceutical industry

CHATHAM, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, held a key opinion leader (KOL) webinar to discuss the positive Phase 3 data of Tonmya™ (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia, and the path to file for FDA approval in the second half of 2024. The webinar was held on January 31, 2024 and hosted by Alliance Global Partners (A.G.P.).

Key Points: 
  • The webinar was held on January 31, 2024 and hosted by Alliance Global Partners (A.G.P.).
  • As previously announced, Tonix’s second positive Phase 3 study, RESILIENT, met its pre-specified primary endpoint, significantly reducing daily pain compared to placebo (p=0.00005) in participants with fibromyalgia.
  • Tonix plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2024 for Tonmya™ for the management of fibromyalgia.
  • “We are now an important step closer to bringing a new, first-line treatment to fibromyalgia patients that offers broad symptom relief and favorable tolerability for chronic use and adherence.”

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

Retrieved on: 
Wednesday, February 14, 2024
Translational medicine, Senior, AML, ALL, Medicine, Syndrome, HCT, Risk, Society, MDS, Therapy, Patient, Acute leukemia, TCR, Transplant, Acute myeloid leukemia, KOL, Cancer

WALTHAM, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss updated results from its Phase 1 heme malignancies study and highlights from its oral presentation at the 2024 Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®) and the Center for International Blood and Marrow Transplant Research (CIBMTR®) on Monday, February 26, 2024, at 8:00 a.m. ET.

Key Points: 
  • ET.
  • The event will provide an in-depth review of the oral presentation related to TScan’s ongoing Phase 1 multi-arm clinical trial evaluating TSC-100 and TSC-101, which are designed to treat residual disease and prevent relapse following hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphocytic leukemia (ALL) ( NCT05473910 ).
  • The Company will also discuss the potential implications of initial data from a large prospective clinical trial assessing the relationship between donor chimerism and risk of relapse.
  • Shrikanta Chattopadhyay, M.D., M.M.Sc., Senior Vice President of Medical and Translational Medicine, TScan Therapeutics

The Concinnity Company Announces a Major Upgrade to its eClinical Trial Management Software

Retrieved on: 
Thursday, February 8, 2024
Cloud, KOL, Ecosystem, Quality of life, ChromeOS, Documentation, Clinical trial, Adobe, DocuSign, Medical imaging

NASHVILLE, Tenn., Feb. 8, 2024 /PRNewswire/ -- The Concinnity Company has announced the release of Cloud ConcinnityⓇ 3.0.0.

Key Points: 
  • NASHVILLE, Tenn., Feb. 8, 2024 /PRNewswire/ -- The Concinnity Company has announced the release of Cloud ConcinnityⓇ 3.0.0.
  • Cloud Concinnity is an integrated software platform for clinical trial oversight.
  • Concinnity was recently named a Top Ten eClinical Trial Management Solution Provider.
  • Cloud Concinnity v3.0.0 is 21 CFR Part 11 compliant with the current Part 11 industry standards.

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Retrieved on: 
Tuesday, February 6, 2024
Molecule, University, Schizophrenia, Retirement, Patient, Safety, BCPP, Pharmacology, Central nervous system, Doctor of Pharmacy, OLE, MPH, CNS, PANSS, RP5063, KOL, Pharmaceutical industry

CUPERTINO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it will host a key opinion leader (KOL) event on Thursday, February 15, 2024 at 12:00 PM ET, featuring Larry Ereshefsky, PharmD, BCPP (Retired professor of Psychiatry, Pharmacology and Psychiatry, The University of Texas; Chief Scientific Officer, Owner, Follow the Molecule LLC) and Mark Opler, PhD, MPH (Chief Research Officer at WCG Inc., Executive Director of the PANSS Institute), who will discuss the unmet medical need and current treatment landscape for patients suffering from acute to chronic symptoms of schizophrenia, and brilaroxazine (RP5063), a next-generation serotonin/dopamine modulator, as a potential treatment.

Key Points: 
  • CUPERTINO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it will host a key opinion leader (KOL) event on Thursday, February 15, 2024 at 12:00 PM ET, featuring Larry Ereshefsky, PharmD, BCPP (Retired professor of Psychiatry, Pharmacology and Psychiatry, The University of Texas; Chief Scientific Officer, Owner, Follow the Molecule LLC) and Mark Opler, PhD, MPH (Chief Research Officer at WCG Inc., Executive Director of the PANSS Institute), who will discuss the unmet medical need and current treatment landscape for patients suffering from acute to chronic symptoms of schizophrenia, and brilaroxazine (RP5063), a next-generation serotonin/dopamine modulator, as a potential treatment.
  • To register, click here .
  • The event will focus on reviewing Reviva's positive topline results and successful completion of pivotal Phase 3 RECOVER trial evaluating the efficacy, safety, and tolerability of once-daily brilaroxazine in adults with acute schizophrenia, as well as the Company's ongoing enrollment in the one-year open label extension (OLE) trial and the initiation of registrational Phase 3 RECOVER-2 trial.
  • A live question and answer session will follow the formal presentations.

Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership

Retrieved on: 
Monday, February 5, 2024
Partnership, CO, Surgeon, FACS, CLARITY, Biomedicine, Biomarker, Patient, ACON, Physician, Biomedical engineering, Algorithm, KOL, Johns Hopkins, Medical device

BROOMFIELD, CO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it has completed several recent financing transactions that have significantly reduced debt and increased available cash. The Company believes these financing transactions will assist in achieving key milestones that include initiating the CLARITY trial, onboarding additional KOL surgeons through the strategic partnership with Alphatec, and continuing to increase Nociscan orders.

Key Points: 
  • The Company believes these financing transactions will assist in achieving key milestones that include initiating the CLARITY trial, onboarding additional KOL surgeons through the strategic partnership with Alphatec, and continuing to increase Nociscan orders.
  • The Company believes these recent financing transactions were on terms more favorable than those available in the public capital markets.
  • The Company expects to add 5 new KOLs to the Nociscan network in the first half of 2024.
  • The Company will provide updates as clinical sites are added to CLARITY and KOLs are onboarded through the strategic partnership.

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

Retrieved on: 
Monday, February 5, 2024
SAN, UCSF, University of California, Pancreatic cancer, CTGF, Pamrevlumab, Virginia Mason Medical Center, MMM, ADC, University, KOL, Pancreatic Cancer Action Network, Pharmaceutical industry

SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM ET.

Key Points: 
  • SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM ET.
  • To register, click here .
  • The second event in the series, to be scheduled at a later date, will include a review of the development program for FG-3246; a Phase 2 ready CD46 targeting antibody-drug conjugate (ADC) for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
  • This series is intended for investor audiences only.

A Decade of Excellence in Wireless Transmission: Wireless Audio and Video Expert Hollyland Emerges Stronger

Retrieved on: 
Friday, February 2, 2024
Life, IBC, Interface (computing), Recognition, Inter, C1, ENC, Cultural diversity, Embrace, Attitude, Sustainability, NAB, Connections, Communication, Red Dot, Patent, Creativity, Trust, Sport, Amazon (company), Innovation, KOL

SHENZHEN, China, Feb. 2, 2024 /PRNewswire/ -- Hollyland has been devoted to producing and manufacturing wireless transmission products for an entire decade. The year 2023 proved to be truly remarkable for Hollyland, marked by resilience, celebration, and innovation.

Key Points: 
  • SHENZHEN, China, Feb. 2, 2024 /PRNewswire/ -- Hollyland has been devoted to producing and manufacturing wireless transmission products for an entire decade.
  • Embracing the theme 'A Year of Above and Beyond', Hollyland found its rhythm, continued to pursue excellence, and made significant strides.
  • The Solidcom C1 Pro is a full-duplex wireless intercom system that utilizes cutting-edge ENC technology to ensure clear communication in noisy environments.
  • Furthermore, Hollyland launched its first-generation livestream camera, VenusLiv, an updated version of the wireless monitor, Mars M1 Enhanced, and an improved iteration of the wireless video transmission, Mars 400S Pro Ⅱ.

EQS-News: Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024

Retrieved on: 
Tuesday, January 30, 2024
Pediatrics, Northwestern University, Patient, Associate, UC, Personalized medicine, Nutrition, Euronext Paris, Division, Hepatology, Therapy, Ulcerative colitis, KOL, EST, Pharmaceutical industry

Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024

Key Points: 
  • Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
    The issuer is solely responsible for the content of this announcement.
  • The event will feature Marla Dubinsky, MD, and Parambir Dulai, MD.
  • Along with Abivax’s management, they will be discussing the unmet medical need and current treatment landscape for patients suffering from ulcerative colitis (UC).
  • He serves as the Director of GI Clinical Trials and Precision Medicine, as well as Director of the Digestive Health Foundation Biorepository.